I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filling system in accordance with 8 1 6(a)(4).

Dated: March 16, 2011 Signature: //MLZ/ (Maria Laccotrice Zacharakis, Ph.D., J.D.) Docket No.: 118160-00301 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Galina V. Mukamolova et al.

Application No.: 09/445,289 Confirmation No.: 9774

Filed: May 11, 2000 Art Unit: 1645

For: BACTERIAL PHEROMONES AND USES Examiner: S. Devi, Ph.D. THEREFOR

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Please find enclosed an English translation as well as the original Chinese document Jing, ER; "Study of resuscitating effect for dormant tuberculosis by recombinant resuscitation promoting factor (Rpf) proteins." *China Journal of Modern Medicine*. (19:17) 2640-43. September 2009. This document was previously cited as cite no. C3 in the IDS filed electronically with the Patent and Trademark Office on March 10, 2011.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 C.F.R. § 1.97(c)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any information referred to herein is "prior art" for this invention unless specifically designated as such.

Application No.: 09/445,289 Docket No.: 118160-00301

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the aforementioned reference.

CONCLUSION

Please charge our Deposit Account No. 50-4876 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-4876, under Order No. 118160-00301.

Dated: March 16, 2011 Respectfully submitted,

By___/MLZ/_

Maria Laccotripe Zacharakis, Ph.D., J.D. Registration No.: 56,266 McCARTER & ENGLISH, LLP

265 Franklin Street Boston, Massachusetts 02110

(617)449-6500 (617)607-9200 Fax

Attorney/Agent For Applicants